News
-
Third trial supports sotatercept to treat PAH
Guidelines expert James R. Klinger, MD, FCCP, said that while the evidence of efficacy is clear, more research is needed to address questions regarding the optimal duration of therapy and the potential for disease progression if therapy is stopped.
-
Study demonstrates strong patient compliance with oral device for OSA
Evidence suggests that an oral device may be an effective alternative for patients who can’t access or tolerate CPAP therapy.
-
The climate cost of inhalers: What prescribers should know
Experts said clinicians must ensure patients have the therapies they need at affordable prices that, ideally, impose minimal amounts of environmental harm.
-
Phase 3 IMPALA-2 clinical trial shows inhaled molgramostim promising for autoimmune pulmonary alveolar proteinosis
An ongoing 96-week, open-label period of the trial is designed to shed light on the drug’s long-term safety and efficacy.
-
Oseltamivir found to lower risk of flu-linked neuropsychiatric events in children
This study is the largest and most comprehensive US investigation of the drug and severe neuropsychiatric events, said author James Antoon, MD, PhD, MPH.
-
Data suggest pneumococcal vaccination is underused
Respiratory medicine expert Christina Thornton, MD, PhD, said recent real-world data demonstrate high rates of community-acquired pneumonia driven by serotypes targeted by vaccines.
-
Early data suggest air pollution may initiate lung cancer
Researcher Peiyao Wang said early results show that fine particulate matter is causing permanent DNA damage, which could have implications for lung cancer screening.
-
Osimertinib plus chemo beat chemo alone in patients with advanced EGFR-mutated NSCLC who advanced on first-line osimertinib
Experts said the results of the COMPEL trial support continued treatment with osimertinib beyond progression in this patient population.
-
SOAR Act in limbo while legislators ride out government shutdown
CHEST Past President John E. Studdard, MD, Master FCCP, said the biggest impact of Medicare competitive bidding has been reduced reimbursement, which has slowed innovation in oxygen delivery.
-
Study explores geographic disparities in tobacco dependence treatment among veterans with COPD
Study author Arianne K. Baldomero, MD, said that reducing geographic barriers will require multidisciplinary approaches and innovative, equitable health care solutions.
